Drugs / KITE-753
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07674823 | Dec 2026 → Apr 2029 expected | B-cell acute lymphoblastic leukemia | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04989803 | Oct 2021 → Feb 2030 expected | B-cell non-Hodgkin lymphoma | Kite, A Gilead Company | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07479797 | May 2026 → May 2031 expected | large B-cell lymphoma | Kite, A Gilead Company | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-12-06 | Kite, A Gilead Company | Results Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025 kitepharma.com ↗
Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, respectively, in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). |
| 2025-12-06 | Gilead Sciences | Results Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025 gilead.com ↗
Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, respectively, in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). |
All press releases naming this drug 2 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KITE-753 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07674823 ↗ |
| Modality | Cell therapy | “A single infusion of CAR-transduced autologous T cells administered intravenously” NCT04989803 ↗ |
| Route | Intravenous | “A single infusion of CAR-transduced autologous T cells administered intravenously” NCT04989803 ↗ |